Apple (AAPL) was downgraded to equal-weight at Barclays. $117 price target. There appears to be limited near-term upside in the company's earnings potential, Barclays said. 

Aetna (AET) was downgraded to market perform at Leerink. $135 price target. The Humana deal stalled and the company is facing challenges in all business segments, Leerink said. 

DineEquity (DIN) was downgraded to neutral from buy at Nomura. $77 price target. Earnings estimates were also cut, given lower sales trends, Nomura reasoned. 

Fred's (FRED) was upgraded to hold at TheStreet Ratings. You can view the full analysis from the report here: FRED.

Performance Food (PFGC) was downgraded to equal-weight from overweight at Barclays. $25 price target. Fundamentals have stalled and cash flow will likely decline in the first half of the year, Barclays said. 

Silgan (SLGN) was upgraded to outperform at BMO Capital. $65 price target. The Westrock deal appears to make both strategic and financial sense, BMO said. 

Xerox (XRX) was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: XRX

This article was written by a staff member of TheStreet.